Organic Bismuth Compound, Method for Producing Same, Living Radical Polymerization Initiator, Method for Producing Polymer Using Same, and Polymer
申请人:Yamago Shigeru
公开号:US20070265404A1
公开(公告)日:2007-11-15
An organobismuth compound represented by the formula (1)
wherein R
1
and R
2
are C
1
-C
8
alkyl, aryl, substituted aryl or an aromatic heterocyclic group, R
3
and R
4
are each a hydrogen atom or C
1
-C
8
alkyl, and R
5
is aryl, substituted aryl, an aromatic heterocyclic group, acyl, amido, oxycarbonyl or cyano.
iron-catalyzed cross-electrophile coupling of aryl chlorides with unactivated alkylchlorides via an iron/B2pin2 catalytic system has been developed. (Hetero)aryl chlorides undergo this transformation smoothly under mild conditions, furnishing the alkylated products with good efficiency. This protocol features excellent functional group compatibility and gram-scale synthesis, which also enables the late-stage functionalization
ORGANIC BISMUTH COMPOUND, METHOD FOR PRODUCING SAME, LIVING RADICAL POLYMERIZATION INITIATOR, METHOD FOR PRODUCING POLYMER USING SAME, AND POLYMER
申请人:Otsuka Chemical Co., Ltd.
公开号:EP1829883B1
公开(公告)日:2011-08-17
US7847043B2
申请人:——
公开号:US7847043B2
公开(公告)日:2010-12-07
[EN] BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE UTILES À TITRE D'AGONISTES INVERSES DE CB-1
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2017035114A1
公开(公告)日:2017-03-02
The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders.